Biotechnology
Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug developm...
2025-12-23 20:00
5050
Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion protein inCell Reports Medicine. The peer-review...
2025-12-23 13:03
4139
Origin Agritech Holds Annual R&D and Operations Management Conference, Establishes 2026 Strategic Priorities
BEIJING, Dec. 22, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, announced the results of its Annual Research & Development and Operations Management Conference held at the Company'sBeijing headquarters from...
2025-12-22 21:36
5063
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therap...
2025-12-22 21:00
7656
T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma
BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblas...
2025-12-21 20:20
3445
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship and transparent disclosure. Climate Change Leadership Being recogn...
2025-12-19 17:30
5834
NEW DRUG APPLICATION FOR TINENGOTINIB TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation ("CDE")of the National Medical Products Administration ("NM...
2025-12-19 09:46
4912
Freda Key C Presents Advanced Recombinant Collagen Delivery Technology at SCC79
Novel Delivery System for High-Molecular-Weight Collagen Advances Anti-Aging Science at the Society of Cosmetic Chemists' Annual Meeting NEW YORK, Dec. 18, 2025 /PRNewswire/ -- Shandong Freda Biotech Co., Ltd. and its medical-aesthetic skincare brand Key C announced the presentation of a novel c...
2025-12-18 22:00
3652
CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion
SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- CorestemChemon (KOSDAQ: 166480)is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supp...
2025-12-18 10:31
2776
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
SAN FRANCISCO and SUZHOU, China, Dec. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-12-18 08:00
4912
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets
TOKYO, Dec. 17, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's a...
2025-12-18 00:00
3816
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics
SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- MEDI&GENE, a
biopharmaceutical company developing therapeutics for metabolic diseases,
announced today that it has entered into a Catalyze agreement with
Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for
obesity.
2025-12-17 21:00
3360
BioTec Sets New Market Standards with Fusion-Based Bio Solutions, Aiming for Global Expansion
SEOUL, South Korea, Dec. 16, 2025 /PRNewswire/ -- BioTec's new releases are attracting attention as technology-fusion solutions rarely seen in the current market. The company's supplement developed with processed sulfur and microbial fermentation offers improved gut health and immune support for ...
2025-12-17 12:10
2246
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced amulti-year, global strategi...
2025-12-17 08:04
2953
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
* The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters * Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials ...
2025-12-16 21:30
2355
Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
BEIJING, Dec. 16, 2025 /PRNewswire/ -- METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates,MTS-105 and MTS-107, have been published in leading international peer-reviewed journals,Nature Communications and theJournal for ImmunoTherapy of Cancer (JITC), representin...
2025-12-16 18:59
3166
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precisi...
2025-12-15 22:00
4571
Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development...
2025-12-15 21:00
2117
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New D...
2025-12-15 18:00
6692
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up ...
2025-12-15 14:06
3949
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
14322
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12990
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
12140
